Lead Sponsor

M.D. Anderson Cancer Center

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.
•No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.
•Life expectancy of at least 12 weeks.
•Performance status equal to or less than Zubrod 2.
•Signed informed consent.
•Patients with measurable disease.
•Age at least 16 years.
•Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.
•Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.
•Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.

•No serious intercurrent illness.
•Adequate contraception (if applicable).
•NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.
•NO experimental clinical trial within 3 weeks of study entry.
•NO patients with active CNS disease.
•Full recovery from any prior surgical treatment.
•NO active active infections.

Related studies

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

NCT06548152 · Chronic Lymphocytic Leukemia

NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more

NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies